Compare ASMB & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | STIM |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 105.5M |
| IPO Year | 2010 | 2018 |
| Metric | ASMB | STIM |
|---|---|---|
| Price | $33.80 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $43.40 | $7.00 |
| AVG Volume (30 Days) | 139.2K | ★ 1.2M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,191,000.00 | ★ $129,873,000.00 |
| Revenue This Year | $33.33 | $101.67 |
| Revenue Next Year | N/A | $10.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 31.30 | ★ 78.61 |
| 52 Week Low | $7.75 | $1.25 |
| 52 Week High | $39.71 | $5.92 |
| Indicator | ASMB | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 42.16 |
| Support Level | $31.51 | $1.36 |
| Resistance Level | $38.99 | $1.64 |
| Average True Range (ATR) | 2.15 | 0.16 |
| MACD | -0.32 | 0.04 |
| Stochastic Oscillator | 33.29 | 29.52 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.